Advisors Asset Management Inc. Has $13.55 Million Position in CVS Health Corporation $CVS

Advisors Asset Management Inc. decreased its stake in CVS Health Corporation (NYSE:CVS) by 5.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 180,039 shares of the pharmacy operator’s stock after selling 9,690 shares during the period. Advisors Asset Management Inc.’s holdings in CVS Health were worth $13,547,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of CVS. Harbor Capital Advisors Inc. increased its holdings in CVS Health by 72.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 142 shares in the last quarter. Avion Wealth grew its holdings in shares of CVS Health by 99.0% during the second quarter. Avion Wealth now owns 380 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 189 shares during the last quarter. Corundum Trust Company INC acquired a new position in shares of CVS Health in the third quarter valued at approximately $29,000. Harbor Asset Planning Inc. bought a new position in CVS Health in the 2nd quarter valued at approximately $30,000. Finally, Front Row Advisors LLC boosted its position in CVS Health by 436.5% during the 2nd quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock worth $31,000 after buying an additional 371 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q4 beat on revenue and adjusted EPS — revenue rose to $105.7B (+8.2%) and adjusted EPS beat consensus ($1.09). The results reflect strength in pharmacy/PBM volume that helps near‑term earnings. CVS Health beats quarterly profit expectations on pharmacy performance
• Positive Sentiment: Operational progress & record top line — full‑year 2025 revenue was a record ~$402.1B; CVS completed the transition to cost‑based pharmacy reimbursement and reported improvements in Aetna prior‑authorization times — positives for margin recovery and execution. CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
• Positive Sentiment: Wall‑street/TV commentary supportive — some market commentators (including Jim Cramer) highlighted catalysts around the turnaround and CEO execution, which can sustain investor interest despite near‑term noise. Jim Cramer on CVS: “I Think It’s a Fascinating Time to Own the Stock”
• Neutral Sentiment: Management reaffirmed multi‑year turnaround targets and emphasized the cost‑based pharmacy model — these are constructive for longer‑term margins but leave short‑term sensitivity to reimbursement and utilization. CVS Health reaffirms $7–$7.20 EPS target for 2026 while advancing cost-based pharmacy model
• Negative Sentiment: FY‑2026 EPS guidance came in below consensus — the company gave a $5.94–$6.14 EPS range that is materially lower than many Street forecasts, a key reason investors sold off after the print. CVS Beats on Q4 Earnings and Revenues but Shares Slide in Pre-Market
• Negative Sentiment: Medicare / MA rate worries — management called a 2027 Medicare Advantage rate notice “disappointing,” saying rates don’t match utilization trends; that raises downside risk to the insurer segment and long‑term margin assumptions. CVS Health CEO Joyner says ‘disappointing’ 2027 MA rate notice fails to match utilization trends
• Negative Sentiment: Cash‑flow and profit headwinds noted — some coverage flagged lowered cash‑flow guidance and that full‑year profit metrics missed certain expectations, which compounds investor concern despite the revenue beat. CVS Health beats Q4 expectations, cash flow guidance lowered CVS Health 2025 profit falls short of $1.8B

CVS Health Stock Performance

NYSE:CVS opened at $75.54 on Wednesday. The company has a quick ratio of 0.63, a current ratio of 0.83 and a debt-to-equity ratio of 0.83. CVS Health Corporation has a twelve month low of $54.06 and a twelve month high of $85.15. The company has a fifty day moving average of $78.52 and a 200-day moving average of $75.98. The firm has a market capitalization of $95.89 billion, a P/E ratio of 198.79, a P/E/G ratio of 0.70 and a beta of 0.50.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The business had revenue of $105.69 billion during the quarter, compared to analysts’ expectations of $103.67 billion. During the same period last year, the company posted $1.19 earnings per share. The business’s quarterly revenue was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, sell-side analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.5%. The ex-dividend date of this dividend was Thursday, January 22nd. CVS Health’s dividend payout ratio is 700.00%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Raymond James Financial upped their price target on shares of CVS Health from $75.00 to $90.00 in a research report on Friday, October 31st. Bank of America decreased their price objective on CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a report on Tuesday, January 27th. UBS Group reaffirmed an “outperform” rating on shares of CVS Health in a research report on Wednesday, December 10th. Argus reduced their price target on CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, January 28th. Finally, Barclays raised their price objective on CVS Health from $87.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Nineteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and an average target price of $94.82.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.